Bromocriptinum

Description
Antiparkinsonian drug, derivative of ergot, dopamine
D2 receptor agonist. Inhibitor of prolactin secretion.
Indications
Parkinson’s disease and syndrome (excluding drug-induced
extrapyramidal symptoms); amenorrhea and
(or) galactorrhea, oligomenorrhea, functional corpus luteum
insufficiency, hyperprolactinemia of various origins,
hyperprolactinemic infertility,
prolactinoma; male hypogonadism; acromegaly;
to suppress lactation (after childbirth, after artificially
terminated pregnancy).
Contraindications
Increased sensitivity to bromocriptine, ergot alkaloids;
pregnancy toxemia; postpartum hypertension. Dosage
For adults. Oral administration. Parkinsonism: 1st
week – 1.25 mg in the evening, increase by 1.25 mg
weekly up to the usual dose of 10-40 mg per day,
taken
2-3 times a day. To suppress lactation: on the day of delivery
– 2.5 mg, then 2.5 mg twice daily
for 14 days. Hypogonadism, infertility, galactorrhea:
initially 1-1.5 mg at bedtime, after 2-3
days increase the dose to 2-2.5 mg at bedtime, then
increase by 1-2.5 mg every 2-3 days; usual dose
– 7.5 mg per day in 2-3 doses; if necessary,
increase the dose to a maximum of 30 mg per day. For prolactinomas:
gradually increase the dose by 2.5 mg every 2-3
days, initially give 2.5 mg every 8 hours, then
2.5 mg every 6 hours. And 5 mg every 6 hours. Administered to patients
up to 30 mg per day. Infertility without
hyperprolactinemia: 2.5 mg twice daily.
Dysmenorrhea (especially breast tenderness): 1-1.25 mg
at bedtime. Acromegaly: initially 1-1.25 mg
at bedtime, gradually increasing the dose to 5 mg
every 6 hours. Tablets are taken with food.
For children. Not recommended for children under 15 years old.
Adverse reactions
Most common: nausea; headache, dizziness,
drowsiness; nasal congestion.
Others: vomiting, gastrointestinal bleeding,
stomach ulcers; vasoconstriction of the fingers or toes,
especially in patients with Raynaud’s phenomenon; confusion,
psychomotor agitation, hallucinations,
dyskinesia, dry mouth, leg cramps,
fluid in the pleural cavity, pleural and lung
fibrosis, pleuritis; retroperitoneal fibrosis; hypotension,
including orthostatic; unusual daytime drowsiness
and sudden onset of sleep; allergic
reactions, hair loss; postpartum women
– hypertension, myocardial infarction, seizures,
stroke or mental disorders.
Pregnancy
Risk category – CM. The incidence of birth defects associated
with bromocriptine is the same as in the general
population.
Breastfeeding
Bromocriptine suppresses lactation, so it is contraindicated
for nursing mothers.
Warnings
When taking the medication, regularly monitor blood pressure,
be cautious when co-administering antihypertensive therapy, do not use
with other ergot alkaloids. Check for pituitary enlargement,
especially in pregnant women. Discontinue drug
use if pregnancy occurs. When taking bromocriptine,
non-hormonal contraceptive methods are recommended.
Administer with caution to patients who have
or have had signs of psychosis, heart or vascular disease,
Raynaud’s syndrome, as well as to those driving
vehicles or operating machinery.

Source | Drug Guide | Lithuanian University of Health Sciences | Institute of Physiology and Pharmacology | Doctor of Medical Sciences Rimas Jankūnas, Doctor of Medical Sciences Arvydas Milašius | Clinic of Internal Diseases | Doctor of Medical Sciences Palmira Leišytė